Post-transplant lymphoproliferative disorders (PTLDs) are a group of conditions that involve
uncontrolled proliferation of lymphoid cells as a consequence of extrinsic …

WITHDRAWN: Executive Summary - The International Society for Heart and Lung
Transplantation (ISHLT) guidelines for the care of heart transplant recipients - ScienceDirect Skip …

A joint working group established by the Haemato‐oncology subgroup of the British
Committee for Standards in Haematology (BCSH) and the British Transplantation Society …

CHAIR: Costanzo MR: Midwest Heart Foundation, Lombard Illinois, USA TASK FORCE 1:
Dipchand A: Hospital for Sick Children, Toronto Ontario, Canada; Starling R: Cleveland …

Purpose Adult post-transplantation lymphoproliferative disease (PTLD) has a reported 3-
year overall survival (OS) of 35% to 40%. The impact of rituximab on the outcome of PTLD is …

Optimal therapy for posttransplant lymphoproliferative disease (PTLD) remains problematic.
A phase II trial adding rituximab to a low-dose cyclophosphamide and prednisone regimen …

Antilymphocyte therapies are widely used for immunosuppression in solid organ
transplantation. These agents have varied mechanisms of action, with resulting differences …

Transplant recipients are vulnerable to a higher risk of malignancy after solid organ
transplantation and allogeneic hematopoietic stem-cell transplant. Post-transplant …

Methotrexate (MTX) carries a risk of lymphoproliferative disorders (LPDs), but MTX-
associated LPDs (MTX-LPDs) can resolve spontaneously after MTX withdrawal. However …

Objectives: The 2015 Workshop of the Society for Hematopathology/European Association
for Haematopathology aimed to review B-cell proliferations of varied malignant potential …